UNSPSC 51171846: Nonabine

This classification denotes an antiemetic agent and antidepressant agent with the molecular formula C25H33NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 77DUK856J7, chemically known as 7-(1,2-dimethylheptyl)-2,2-dimethyl-4-(4-pyridyl)-2h-1-benzopyran-5-ol but generally known as nonabine, which bears US NIH Compound Identifier 71885. European Medicines Agency schedules Nonabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09348MIG.

UNSPSC 51171846 Nonabine, a Commodity code, describes pharmaceutical products and testing services that state and local government agencies and cooperative purchasing organizations procure for corrections departments, health agencies, and multi-state purchasing alliances. State and local buyers under this code include county corrections departments, state health and human services commissions, and multi-state cooperative purchasing entities. The recent solicitations show demand for drug testing services (specimen collection, screening, and confirmation testing), direct-to-manufacturer pharmaceutical distribution programs, and generic multi-source pharmaceuticals and over-the-counter products for government facilities.

Recent activity spans Texas, Minnesota, and Oregon. Collin County Community Supervision and Corrections Department (Texas) issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with proposals due July 23, 2026 at 2:00 p.m., estimated contract value $600,000 for two years commencing September 1, 2026, with anticipated award August 10, 2026; the scope includes staffing two sites in Plano and McKinney, immunoassay and mass spectrometry screening and confirmation, and approximately 25,031 annual tests across multiple panel types. The Texas Health and Human Services Commission issued RFI HHS0017013 on March 27, 2026, with response deadline April 3, 2026, to gather vendor capabilities and market intelligence on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity with self-insured health plans and state agencies outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract effectiveness July 1, 2026; evaluation is weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and remaining points on compliance, EDI capability, and administrative fee structure.